Evidence map›Paper›PMID 35975265›Full record

ReviewActa endocrinologica (Bucharest, Romania : 2005)

UPDATED UNDERSTANDING OF THE MOLECULAR TARGETS OF RADIOIODINE IN DIFFERENTIATED THYROID CANCER.

Y Zhang, W Zou, X Zhu, L Jiang, C Gui, Q Fan, Y Tu, J Chen

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta endocrinologica (Bucharest, Romania : 2005). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. PAPILLARY MICROCARCINOMA OF THE THYROID GLAND - DOES SIZE MATTER?Acta endocrinologica (Bucharest, Romania : 2005)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Y ZhangHubei Cancer Hospital - Department of Head and Neck Surgery, Wuhan, China.
W ZouFirst People's Hospital of Yichang - Department of General Surgery II, Yichang, Hubei, China.
X ZhuHubei Cancer Hospital - Department of Head and Neck Surgery, Wuhan, China.
L JiangHubei Cancer Hospital - Department of Head and Neck Surgery, Wuhan, China.
C GuiHubei Cancer Hospital - Department of Head and Neck Surgery, Wuhan, China.
Q FanHubei Cancer Hospital - Department of Head and Neck Surgery, Wuhan, China.
Y TuLiuzhou Traditional Chinese Medical Hospital - Department of Otolaryngology & Head and Neck Surgery, Liuzhou, Guangxi, China.
J ChenHubei Cancer Hospital - Department of Head and Neck Surgery, Wuhan, China.
Hubei Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radioactive iodine (RAI) therapy is a mainstay adjuvant treatment for thyroid cancer. Administration of RAI therapy after total or near-total thyroidectomy has shown a survival advantage in numerous properly selected patients. However, the role of RAI therapy after reoperation for persistent or recurrent differentiated thyroid carcinomas (DTCs) is unclear. One reason may be the possible downregulation of the I- transport system after primary surgery. RAI is transported by the sodium iodide symporter (NIS), PENDRIN, anoctamin 1 (ANO1) and cystic fibrosis transmembrane conductance regulator (CFTR) and emits β particles that destroy follicular cells. The identification of pathways of iodide (I-) transport has allowed use of the transport system to render tumours susceptible to RAI treatment

Indexed as

iodine transport systemI- uptakeRadioactive iodine (RAI)thyroid cancer

Identifiers

PMID35975265
PMCPMC9365402
OpenAlexW4290659274

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.